Why is Immunovant stock surging today?

Immunovant stock surged 12.8% in morning trading after the Durham, N.C.-based immunology company reported fiscal second-quarter results before the opening bell that dramatically beat Wall Street expectations, while simultaneously unveiling positive Phase 2b clinical data for its lead drug candidate. The company posted a loss of $0.41 per share for the quarter ended September 30, 2026, well ahead of the analyst consensus calling for a loss of $0.74 — a positive surprise of $0.33 per share. Alongside the earnings release, Immunovant disclosed that IMVT-1402 at the 600 mg dose met the primary endpoint in its potentially registrational trial for difficult-to-treat rheumatoid arthritis, achieving a 92.5% ACR20 response rate at Week 28 compared to 75.6% for placebo, a statistically significant result.

The financial improvement was broad-based, with the quarterly net loss narrowing to $97.2 million from $126.5 million in the same period a year earlier, driven in part by a meaningful reduction in non-GAAP R&D expenses to $78.5 million from $106.5 million year-over-year. Management also announced plans to engage with the FDA later this year to map out the registrational path forward for IMVT-1402 in difficult-to-treat rheumatoid arthritis, a signal that the company sees a clear route toward a potential approval. The strong results helped restore investor confidence that had been shaken in September when the company discontinued IMVT-1402 development in cutaneous lupus erythematosus after a proof-of-concept study failed to achieve statistical significance on its primary endpoint. Analysts currently maintain a "Moderate Buy" consensus on the stock with an average price target of $44.

The broader market provided a supportive backdrop, with the S&P 500 gaining 1.2%, the Dow Jones rising 1.1%, and the Nasdaq advancing 1.5%, creating favorable conditions for risk assets and amplifying the stock-specific catalyst. Parent company Roivant Sciences also reported its own strong quarterly results today, with its newly launched LISRAYA generating $31 million in net revenue in its first five weeks on the market, adding a positive halo effect across the Roivant ecosystem. The company did file a mixed shelf registration statement today, which could signal future capital raises, but investors appeared to look past this in light of the day’s stronger news.

Together, the combination of a substantial earnings beat, transformative clinical trial success in a high-unmet-need indication, and a constructive market environment converged to push Immunovant shares sharply higher, with the stock trading at $34.45 — well off its 52-week low of $21.43 but still meaningfully below its 52-week high of $45.42, suggesting further room for recovery if the pipeline momentum continues.